Filip Janku, MD, PhD, discusses the results form a phase 1 study of ripretinib, a broad-spectrum KIT and PDGFRA inhibitor, in patients with KIT-mutated or KIT-amplified melanoma.
Filip Janku, MD, PhD
Advertisement
Articles by Filip Janku, MD, PhD
Filip Janku, MD, PhD, discusses longitudinal monitoring of BRAF V600E mutation in urinary cell-free DNA of patients with metastatic cancers.
Advertisement
Latest Updated Articles
Dr. Janku on the Efficacy of Ripretinib in KIT-Mutated MelanomaPublished: September 17th 2021 | Updated:
Dr. Janku on Longitudinal Monitoring of BRAF V600E Mutation in Urinary Cell-Free DNAPublished: July 21st 2014 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
2
NP-G1-044 Receives FDA Orphan Drug Designation for Pancreatic Cancer
3
Ixazomib-Based Regimens Expand Options in Relapsed/Refractory Multiple Myeloma
4
FDA Advises on Next Steps for Nogapendekin Alfa Inbakicept Plus BCG sBLA in BCG-Unresponsive Papillary NMIBC
5